Cornerstone accepts Chiesi proposal after long courtship
This article was originally published in Scrip
Chiesi Farmaceutici will acquire the 42% of outstanding Cornerstone Therapeutics shares that the private Italian pharmaceutical company does not already own for $9.50 per share, valuing the hospital- and specialty market-focused Cornerstone at roughly $252m.
You may also be interested in...
Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.